We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Port Erin | LSE:PEBI | London | Ordinary Share | IM00B6QH1J21 | ORD 0.0001P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 4.50 | 4.00 | 5.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMPEBI
RNS Number : 9529T
Port Erin Biopharma Investments Ltd
12 January 2017
Port Erin Biopharma Investments Limited
(the "Company")
Net Asset Value calculation to 31 December 2016
Jim Mellon, Chairman, commented: -
"The Net Asset Value ("NAV") calculation for the Company as at closing on 31 December 2016 was 11.13 pence per share, including un-invested cash of GBP66,642. The portfolio is valued under IFRS at bid price.
Net Assets stand at GBP2.62 million including investments of GBP2.55 million. This quarter's NAV represents an increase of 11.7% from the previous valuation of 9.96 pence per share, which included un-invested cash of GBP12,921. No management fee is due to Shellbay Investments Limited.
The increase in reported NAV to 31 December 2016 is mainly due to an upturn in the value of the holding in Regent Pacific Group. The Company's three principal investments continue to show significant growth potential during 2017 and beyond".
Hot Features
Premium
Unaudited to 31 December 2016 GBP
Fixed Assets
Investments 2,548,237
Current Assets
Sundry Debtors 8,592
Uninvested cash 66,642
Current Liabilities
Creditors: amounts due (41,962)
---------------------------------
2,581,509
Capital and Reserves
Share Capital 23
Share Premium 1,890,142
Reserves 691,344
---------------------------------
2,581,509
Shares in Issue 23,195,558
Net Asset Value per share 11.13 pence
Portfolio Details
Investments as at 31 Value % of Total Portfolio December 2016 ------------------------- ------------- -------------------- Magna Biopharma Income Fund GBP953,318 37.41% Regent Pacific Group GBP740,148 29.05% Summit Corporation GBP170,706 6.70% Investment loans GBP200,000 7.85% Other quoted holdings GBP136,845 5.37% Other unquoted holdings GBP347,220 13.62% Total GBP2,548,237 100.00% ------------------------- ------------- --------------------
For further information, please contact:
Port Erin Biopharma Northland Capital Partners Peterhouse Capital
Investments Limited Limited Limited
The Company Nomad and Broker Broker
Denham Eke Matthew Johnson / David Lucy Williams
(+44) (0) 1624 639396 Hignell (+44) (0) 207
(+44) (0) 203 861 6625 469 0936
This information is provided by RNS
The company news service from the London Stock Exchange
END
NAVMMGMMNMRGNZM
(END) Dow Jones Newswires
January 12, 2017 02:00 ET (07:00 GMT)
1 Year Port Erin Chart |
1 Month Port Erin Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
